Panacea Index Logo

Command Palette

Search for a command to run...

Ketamine: An emerging agent in the management of neuropsychiatric disorders.

Asian journal of psychiatry
April 1, 2025
Nathan Menke et al. (4 authors)
Journal ArticleReviewHuman Study
Study Details

Study Goal

The researchers aimed to provide an overview of ketamine's pharmacology and discuss its emerging uses beyond anesthesia, focusing on neuropsychiatric disorders and other conditions.

Results Summary

The study highlights ketamine's potential in treating substance use disorders, withdrawal syndromes, pain syndromes, and psychomotor agitation, in addition to its established role in depression and suicidality. It emphasizes ketamine's unique pharmacological profile and neuroplastic effects.

Population

Patients with neuropsychiatric disorders, substance use disorders, withdrawal syndromes, pain syndromes, and severe psychomotor agitation.

Effective Dosage

Not specified

Duration

Not specified

Interactions

None mentioned

Extracted Claims (6)
InterventionDirectionEndpointPopulationDosageImpactClaim #
ketamine
neutral
a wide range of neuropsychiatric disorders
-
-
make it a subject of study with implications for
#1
ketamine
neutral
substance use disorders (alcohol, cannabis, cocaine, and opioids)
-
-
emerging use in treating
#2
ketamine
neutral
withdrawal syndromes (opioid and alcohol)
-
-
emerging use in treating
#3
ketamine
neutral
acute and chronic pain syndromes
-
-
emerging use in treating
#4
ketamine
neutral
severe psychomotor agitation
-
-
emerging use in treating
#5
ketamine
neutral
depression and suicidality
-
-
treatment of
#6
Abstract

Ketamine's unique pharmacological profile, safety, modulation of multiple neurotransmitter systems, and ability to produce neuroplastic changes make it a subject of study with implications for a wide range of neuropsychiatric disorders beyond its traditional use as an anesthetic agent. This article aims to provide an overview of the pharmacology of ketamine and briefly discuss its emerging use in treating: substance use disorders (alcohol, cannabis, cocaine, and opioids); withdrawal syndromes (opioid and alcohol); acute and chronic pain syndromes; and severe psychomotor agitation. Ketamine for the treatment of depression and suicidality is well established; however, the focus of this paper is to outline less common indications.

Medical Subject Headings (MeSH)
HumansKetamineSubstance-Related DisordersSubstance Withdrawal SyndromePsychomotor AgitationMental Disorders
Study Links
Quality Scores
Safety75
Efficacy80/10
Quality70/10
Research Impact Scores
APT Score0.05
Weight Score2.40
Normalized Score0.76
Related Supplements